British pharmaceutical company AstraZeneca (AZ) is reportedly in discussions with U.S.-based Bristol Myers Squibb (BMS) regarding a potential merger. If successful, the combined market capitalization of the two companies would be approximately $400 billion, making it the fourth-largest pharmaceutical company in the world.
According to the Financial Times and Reuters on August 2, the two companies have engaged in initial merger talks over the past few months. However, it remains unclear whether negotiations are still ongoing, and there is a possibility that discussions could stall or the merger could fall through.
AstraZeneca's market capitalization is around £196 billion, while BMS stands at approximately $133 billion. The $400 billion figure is not a confirmed acquisition price but rather a combined market cap based on current stock prices.
If the merger goes through, AZ would enhance its presence and scale in the U.S., the largest pharmaceutical market globally. Meanwhile, BMS is in need of new growth avenues to address the expiration of patents on its key drugs and competition from generics.
The most significant variable in this process is the U.S. regulatory review of the merger. Both companies have cancer drugs as their core business, and some treatments directly compete with each other. If their drug development areas overlap, U.S. authorities may require the divestiture of certain products or business units as a condition for merger approval.
Concerns may also arise in the U.K. AZ expanded its connection to the U.S. capital markets by directly listing its common stock on the New York Stock Exchange on February 2. While it maintains listings on the London and Stockholm stock exchanges, a merger with BMS could tilt the company's operations and investor base further toward the U.S.
AstraZeneca declined to comment on the merger discussions, and BMS did not respond immediately to inquiries.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.